Skip to main content
. 2016 Sep 12;11(9):e0162754. doi: 10.1371/journal.pone.0162754

Fig 2. TNBCSC and non-CSC sensitivity to TRAIL treatment.

Fig 2

(A) Sensitivity of MCF-10A and breast cancer stem cells and non-stem cells to TRAIL was determined via MTT assays. *P<0.05, t test. (B) The IC50 of TRAIL was determined according to the cell viability curves calculated based on the MTT assay results. *P<0.05, t test.